Analysis of influencing factors in patients with chronic liver disease complicated with osteoporosis

Abstract

Abstract: Objective To analyze the influencing factors of osteoporosis in patients with chronic liver disease. Methods This study retrospectively collected 215 outpatients and inpatients with liver diseases from the Xinjiang Urumqi Autonomous Region Hospital of Traditional Chinese Medicine and the Xinjiang Changji Hui Autonomous Prefecture Hospital of Traditional Chinese Medicine between September 2023 and June 2024. The clinical data, such as demographic information, serological indexes and nutritional risk, were collected to calculate CTP score and MELD. Patients were divided into osteoporosis group and non-osteoporosis group. Furthermore, multivariate logistic regression analysis was used to screen the risk factors of osteoporosis in patients with chronic liver disease. Results The prevalence of osteoporosis in patients with chronic liver disease was 22.3% . Among the causes of chronic liver disease, chronic hepatitis, primary cholangitis, autoimmune hepatitis and other causes were significantly different between two groups(P<0.05) . There were significant differences between the two groups in age, BMI (P<0.05) , ALP, Alb, DBil , TBA, ChE, BUN, Cys-c,β2-MG, serum calcium and MELD (P<0.05) . In nutrition risk assessment, there were significant differences in nutrition score and nutrition risk (P<0.05) . Multivariate Logistic regression analysis showed that nutritional risk (OR=1.934,95%CI:1.264~2.959 , P=0.002)and age(OR=1.074,95%CI:1.031~1.120, P=0.001 )were risk factors of osteoporosis in patients with chronic liver disease. Conclusion Nutritional risk and age are risk factors of osteoporosis in patients with chronic liver disease.

Key words: Chronic liver disease, Osteoporosis, Nutrition risks, Influencing factors

JING Jin-hua, MA Chao, LI Yu-yu, NING Zhong-hui, DOU Jing, WANG Xiao-bo, DING Guo-ning, WANG Xiao-zhong, GUO Feng. Analysis of influencing factors in patients with chronic liver disease complicated with osteoporosis[J]. Chinese Hepatolgy, 2025, 30(11): 1561-1567.

References

[1] 周丽智,黄鑫,唐兰燕,等. 肝性骨病发病机制的研究进展[J]. 中南医学科学杂志,2022,50(4):614-617.
[2] Núria, Guañabens, Albert, et al. Osteoporosis in chronic liver disease[J]. Liver Int, 2018,38(5):776-785.
[3] Peng Y, Xi S, Huang R. Association between hepatitis B virus infection and risk of osteoporosis:a systematic review and meta-analysis[J]. Asian J Surg,2023, 46(10):4598-4600.
[4] Ehnert S, Aspera-Werz R H, Ruoß M, et al. Hepatic osteodystrophy-molecular mechanisms proposed to favor its development[J]. Int J Mol Sci,2019,20(10): 2555.
[5] Ebeling P R, Nguyen H H, Aleksova J, et al. Secondary osteoporosis[J]. Endocr Rev,2022,43(2):240-313.
[6] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志,2023,26(3):后插1-后插22.
[7] 中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华肝脏病杂志,2022,30(12):1332-1348.
[8] 中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南(2021)[J]. 中华肝脏病杂志,2022,30(3):264-275.
[9] 中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021)[J]. 中华肝脏病杂志,2022,30(5):482-492.
[10] 中国中西医结合学会,中华中医药学会,中华医学会,等. 肝硬化中西医结合诊疗指南[J]. 临床肝胆病杂志,2023,39(11):2543-2549.
[11] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志,2018,34(5):939-946.
[12] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022)[J]. 中华骨质疏松和骨矿盐疾病杂志,2022,15(6):573-611.
[13] Lee H S, Choi G H, Joo D J, et al. Prognostic value of model for end-stage liver disease scores in patients with fulminant hepatic failure[J]. Transplant Proc,2013, 45(8):2992-2994.
[14] 周新兰,马鑫,王雁冰,等. APRI、FIB-4和GPR对慢性乙型肝炎肝脏炎症程度的诊断价值[J]. 临床肝胆病杂志,2021,37(9):2066-2070.
[15] 中华医学会肠外肠内营养学分会,营养风险-不足-支持-结局-成本/效果多中心协作组,张献娜,等. 营养风险筛查和全球(营养)领导人发起的营养不良诊断(GLIM)第二、三步流程(共识2020)[J]. 中华临床营养杂志,2020,28(4):193-200.
[16] Wang L, Yu W, Yin X, et al. Prevalence of osteoporosis and fracture in China: the China osteoporosis prevalence study[J]. JAMA Netw Open,2021,4(8): e2121106.
[17] Wong W J, Emdin C, Bick A G, et al. Clonal haematopoiesis and risk of chronic liver disease[J]. Nature,2023,616(7958):747-754.
[18] Muratori L, Lohse A W, Lenzi M. Diagnosis and management of autoimmune hepatitis[J]. BMJ,2023,380:e070201.
[19] Lonele C M, Turcu-Stiolica A, Subtirelu M S, et al. Osteoporosis assessment among adults with liver cirrhosis[J]. J Clin Med,2022,12(1):153.
[20] Kobayashi K, Imagama S, Ando K, et al. Epidemiology and effect on physical function of osteosarcopenia in community-dwelling elderly people in Japan[J]. Mod Rheumatol,2020,30(3):592-597.
[21] Park K S, Lee G Y, Seo Y M, et al. Disability,frailty and depression in the community-dwelling older adults with Osteosarcopenia[J]. BMC Geriatr,2021,21 (1):69.
[22] Yang Y J, Kim D J. An overview of the molecular mechanisms contributing to musculoskeletal disorders in chronic liver disease:osteoporosis,sarcopenia, and osteoporotic sarcopenia[J]. Int J Mol Sci,2021,22(5):2604.
[23] 王君,朱志军,曲伟,等. 成人慢性肝病患者肝移植前的骨质疏松症风险评估[J]. 临床和实验医学杂志,2019,18(20):2186-2190.
[24] Oh H, Jun D W, Lee I H, et al. Increasing comorbidities in a South Korea insured population-based cohort of patients with chronic hepatitis B[J]. Aliment Pharmacol Ther,2020,52(2):371-381.
[25] Olmos-Martínez J M, Hernández J L, Fábrega E, et al. Bone mineral density and trabecular bone score in treatment-naïve patients with non-cirrhotic hepatitis C virus infection[J]. Arch Osteoporos,2020,15(1):72.
[26] Lonele C M, Turcu-Stiolica A, Subtirelu M S, et al. A systematic review and meta-analysis on metabolic bone disease in patients with primary sclerosing cholangitis[J]. J Clin Med,2022,11(13):3807.
[27] Ciardullo S, Perseghin G. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes[J]. Metabolism,2021, 121:154752.
[28] Hejazi J, Davoodi A, Khosravi M, et al. Nutrition and osteoporosis prevention and treatment. Biomed Res Ther,2020,7, 3709-3720.
[29] Jiang B C, Villareal D T. Weight loss-induced reduction of bone mineral density in older adults with obesity[J]. J Nutr Gerontol Geriatr,2019,38(1):100-114.
[30] Fahimfar N, Noorali S, Yousefi S, et al. Prevalence of osteoporosis among the elderly population of Iran[J]. Arch Osteoporos,2021,16(1):16.